Among patients with AD, GLP-1 RAs reduced the risk for various MACE outcomes, including heart failure, cerebrovascular disease, and more.

Tralokinumab is effective and safe for the treatment of patients with moderate to severe AD through 6 total years of treatment.

Quality of life outcomes were examined based on the presence and severity of hand eczema among patients with atopic dermatitis.

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...

Historically good results with IL-4 inhibitors raise questions with U.S. audience ...

A topic dermatitis is a chronic condition that tends to rear its itchy head during certain periods before subsiding — for months, possibly, or even years. It particularly affects the insides of the ...

Patients with atopic dermatitis who receive treatment with dupilumab may be at an increased risk for new-onset vitiligo.

Credit: Getty Images. Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

A higher maternal prepregnancy BMI and greater birth length are associated with an elevated risk for atopic dermatitis in ...

In patients with moderate atopic dermatitis, the use of Opzelura (ruxolitinib) led to early and sustained improvements in ...

The most common concerns include which foods might cause or trigger atopic dermatitis, when to introduce solid foods, and ...